Neoantigen quality predicts immunoediting in survivors of pancreatic cancer

Cancer immunoediting(1) is a hallmark of cancer(2) that predicts that lymphocytes kill more immunogenic cancer cells to cause less immunogenic clones to dominate a population. Although proven in mice(1,3), whether immunoediting occurs naturally in human cancers remains unclear. Here, to address this...

Descripción completa

Detalles Bibliográficos
Autores principales: Łuksza, Marta, Sethna, Zachary M., Rojas, Luis A., Lihm, Jayon, Bravi, Barbara, Elhanati, Yuval, Soares, Kevin, Amisaki, Masataka, Dobrin, Anton, Hoyos, David, Guasp, Pablo, Zebboudj, Abderezak, Yu, Rebecca, Chandra, Adrienne Kaya, Waters, Theresa, Odgerel, Zagaa, Leung, Joanne, Kappagantula, Rajya, Makohon-Moore, Alvin, Johns, Amber, Gill, Anthony, Gigoux, Mathieu, Wolchok, Jedd, Merghoub, Taha, Sadelain, Michel, Patterson, Erin, Monasson, Remi, Mora, Thierry, Walczak, Aleksandra M., Cocco, Simona, Iacobuzio-Donahue, Christine, Greenbaum, Benjamin D., Balachandran, Vinod P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177421/
https://www.ncbi.nlm.nih.gov/pubmed/35589842
http://dx.doi.org/10.1038/s41586-022-04735-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177421/
https://www.ncbi.nlm.nih.gov/pubmed/35589842
http://dx.doi.org/10.1038/s41586-022-04735-9

Ejemplares similares